T-Vec is a first-in-class, injectable, intralesional oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
If you have a Hayes login, click here to view the full report on the Knowledge Center.